A clinical trial published in the journal Nature Communications recently reported a method for assessing the use of fluorescent tracers to determine tumor margins during breast cancer surgery. The results of the test indicate that the fluorescent tracer bavacizumab-800CW is safe and can significantly improve the detection of tumor margins in breast cancer patients.
During tumor resection, the surgeon relies on visual inspection and palpation to detect the edge of the tumor, but this method is inaccurate. Fluorescent tracers allow targeting of tumor cells, which are being tested in clinical trials, but lack standardized methods for determining the efficacy of fluorescent tracers. In addition, current methods are not easy to perform intraoperative monitoring, and require time-consuming tissue sectioning, or techniques such as computed tomography and magnetic resonance imaging, which are not available in real time during surgery.
This time, the research team at the University of Groningen Medical Center in the Netherlands reported the results of a clinical dose escalation trial. The aim of this trial was to evaluate the efficacy of the fluorescent tracer bavacizumab-800CW in 26 patients with breast cancer surgery, which was applied to the current surgical procedure to detect tumor margins in real time.
The results of the study showed that fluorescence imaging was safe and increased the detection rate of tumor margins by 88%. Further research is needed to determine whether the technique can reduce the number of tumor-positive margins (where the outer edge of the removed cancer tissue is present) during breast-conserving surgery and reduce the rate of secondary surgery after surgery.
Lactobacillus Gasseri,Lactobacillus Gasseri Probiotic,Lactobacillus Gasseri Products,Lactobacillus Gasseri Supplement
Biodep Biotechnology Co. ,Ltd. , https://www.mbioda.com